cannabis indica

Obesidade

termo de indexação original: Obesity

O acervo do Cannabis Indica reúne 237 estudos científicos que tocam a condição Obesidade, publicados entre 2000 e 2024. Pela leitura automatizada, 174 (73%) foram classificados como favoráveis, 31 (13%) como inconclusivos e 32 (14%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (85 estudos), seguido de estudo em animais (53). Os compostos mais presentes são Endocanabinoide (não especificado), Anandamida (AEA) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Síndrome Metabólica, Diabetes e Inflamação.

Estudos indexados
237
Período coberto
2000–2024
Favoráveis
174 · 73%
Inconclusivos
31 · 13%
Desfavoráveis
32 · 14%
Termo original
Obesity

O acervo em números

Tipo de estudo

Metanálise85
Estudo em Animais53
Ensaio Clínico44
Ensaio Clínico Duplo-Cego35
Estudo Laboratorial11
Metanálise Clínica9

Direção do resultado

Favorável174
Inconclusivo31
Desfavorável32

Por década

2000s29
2010s106
2020s102

237 estudos

Filtrar e buscar no acervo →
  1. 2024

    Cold-induced changes in plasma signaling lipids are associated with a healthier cardiometabolic profile independently of brown adipose tissue

  2. 2024

    Dietary linoleic acid lowering alone does not lower arachidonic acid or endocannabinoids among women with overweight and obesity: A randomized, controlled trial

  3. 2024

    Harmonization of clinical practice guidelines for primary prevention and screening: actionable recommendations and resources for primary care

    InconclusivoMetanáliseDependência QuímicaCâncerDependência — Cannabis+11
  4. 2024

    Nutrient composition of different energy-restricted diets determines plasma endocannabinoid profiles and adipose tissue DAGL-α expression; a 12-week randomized controlled trial in subjects with abdominal obesity

  5. 2024

    Perioperative Cannabis Use in Bariatric Patients: A Review of Outcomes and Proposed Clinical Pathway for Management

    DesfavorávelMetanáliseDorDependência QuímicaEfeitos Adversos da Cannabis+9
  6. 2024

    Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile

  7. 2024

    The circulating and central endocannabinoid system in obesity and weight loss

    InconclusivoMetanáliseAnandamida (AEA)Endocanabinoide (não especificado)+1
  8. 2023

    A Case of a Patient With Cannabis Hyperemesis Syndrome Along With Recurrent Nephrolithiasis

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da Cannabis+7
  9. 2023

    A daily diary investigation of cannabis use and its diet and exercise correlates

  10. 2023

    Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoTetraidrocanabinol (THC)THC Farmacêutico+25
  11. 2023

    Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3

  12. 2023

    Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study

    FavorávelEnsaio Clínico Duplo-CegoSíndrome MetabólicaEndocanabinoide (não especificado)
  13. 2023

    Effects of eight-week regular high-intensity interval training and hemp (Cannabis sativa L.) seed on total testosterone level among sedentary young males: double-blind, randomized, controlled clinical trial

    FavorávelEnsaio Clínico Duplo-CegoEstresse OxidativoSíndrome Metabólica
  14. 2023

    Palmitoylethanolamide counteracts high-fat diet-induced gut dysfunction by reprogramming microbiota composition and affecting tryptophan metabolism

  15. 2023

    Therapeutic effect of cannabidiol on myocardial arachidonic acid content in various lipid fractions in a rat model of obesity

  16. 2022

    (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  17. 2022

    Cannabidiol Downregulates Myocardial de Novo Ceramide Synthesis Pathway in a Rat Model of High-Fat Diet-Induced Obesity

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Síndrome Metabólica
  18. 2022

    Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department

  19. 2022

    Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  20. 2022

    Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

  21. 2022

    Cannabis Use as a Protective Factor Against Overweight in HIV-Hepatitis C Virus Co-Infected People (ANRS CO13 HEPAVIH Cohort)

    FavorávelMetanáliseSíndrome MetabólicaHIV/AIDSHepatite
  22. 2022

    Cloudy with a chance of munchies: Assessing the impact of recreational marijuana legalization on obesity

    FavorávelMetanáliseEfeitos Adversos da Cannabis
  23. 2022

    Downregulation of hepatic fat accumulation, inflammation and fibrosis by nerolidol in purpose built western-diet-induced multiple-hit pathogenesis of NASH animal model

    FavorávelEstudo em AnimaisInflamaçãoSíndrome MetabólicaFibrose+2
  24. 2022

    Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

    FavorávelMetanáliseAnsiedadeEpilepsiaDiabetesTetraidrocanabinol (THC)+5
  25. 2022

    Effects of Omega-3 Supplementation on Components of the Endocannabinoid System and Metabolic and Inflammatory Responses in Adipose and Liver of Peripartum Dairy Cows

    InconclusivoEstudo em AnimaisInflamaçãoAnandamida (AEA)Outros Compostos Relacionados+1
  26. 2022

    Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota

  27. 2022

    Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults

  28. 2022

    Inhalation of low-dose basil (Ocimum basilicum) essential oil improved cardiovascular health and plasma lipid markers in high fat diet-induced obese rats

  29. 2022

    Interpreting Clinical Trials With Omega-3 Supplements in the Context of Ancestry and FADS Genetic Variation

  30. 2022

    Omega 3 Fatty Acid and Cannabidiol Prolong Lifespan and Ameliorates Brain Ischaemia in Mice Fed Chronic High Fat Diet

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoAVCÔmega-3+1
  31. 2022

    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice

  32. 2022

    Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial

  33. 2022

    Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

    DesfavorávelEnsaio Clínico Duplo-CegoAnsiedadeDoenças Cardiovasculares (DCV)DepressãoCanabinoides Sintéticos SR-x+1
  34. 2022

    Role of the major terpenes of Callistemon citrinus against the oxidative stress during a hypercaloric diet in rats

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoSíndrome Metabólica
  35. 2022

    Sex differences in endocannabinoids during 3 years of Mediterranean diet intervention: Association with insulin resistance and weight loss in a population with metabolic syndrome

  36. 2022

    The effect of β-caryophyllene on food addiction and its related behaviors: A randomized, double-blind, placebo-controlled trial

  37. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  38. 2022

    The Mediterranean Diet as a Source of Bioactive Molecules with Cannabinomimetic Activity in Prevention and Therapy Strategy

    FavorávelMetanáliseSíndrome MetabólicaDieta
  39. 2022

    The Metabolic Efficacy of a Cannabidiolic Acid (CBDA) Derivative in Treating Diet- and Genetic-Induced Obesity

  40. 2022

    The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism

  41. 2022

    The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer

  42. 2022

    Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    FavorávelMetanálise ClínicaDorInflamaçãoDisfunção CognitivaPalmitoiletanolamida (PEA)+8
  43. 2022

    Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome

  44. 2022

    Vitamin D mitigates diabetes-associated metabolic and cognitive dysfunction by modulating gut microbiota and colonic cannabinoid receptor 1

    FavorávelEstudo em AnimaisDisfunção CognitivaDiabetesSíndrome MetabólicaMicrobioma+1
  45. 2021

    A Role for Peripheral Anandamide and 2-Arachidonoylglycerol in Short-Term Food Intake and Orexigenic Hypothalamic Responses in a Species with Continuous Nutrient Delivery

  46. 2021

    Acute effects of hemp protein consumption on glycemic and satiety control: results of two randomized crossover trials

    FavorávelEnsaio ClínicoDiabetesSíndrome Metabólica
  47. 2021

    Associations of Serum Fatty Acid Proportions with Obesity, Insulin Resistance, Blood Pressure, and Fatty Liver: The Cardiovascular Risk in Young Finns Study

  48. 2021

    At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk

  49. 2021

    Attenuation of Oxidative Stress and Inflammatory Response by Chronic Cannabidiol Administration Is Associated with Improved n-6/n-3 PUFA Ratio in the White and Red Skeletal Muscle in a Rat Model of High-Fat Diet-Induced Obesity

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoSíndrome Metabólica+1
  50. 2021

    Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists

  51. 2021

    Caloric restriction, physical exercise, and CB1 receptor blockade as an efficient combined strategy for bodyweight control and cardiometabolic status improvement in male rats

  52. 2021

    Cannabidiol - A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDoença de AlzheimerDiabetes+1
  53. 2021

    Cannabinoids modulate food preference and consumption in Drosophila melanogaster

    FavorávelEstudo em AnimaisSíndrome MetabólicaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  54. 2021

    Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target

    FavorávelMetanáliseInflamaçãoTetraidrocanabivarina (THCV)
  55. 2021

    Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

    FavorávelMetanáliseHepatite
  56. 2021

    Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids

  57. 2021

    Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors

  58. 2021

    Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial

    FavorávelEnsaio Clínico Duplo-CegoInsuficiência HepáticaEsteatose HepáticaOleoiletanolamida (OEA)
  59. 2021

    GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+2
  60. 2021

    Hempseed (Cannabis sativa) offers effective alternative over statins in ameliorating hypercholesterolemia associated nephropathy

    FavorávelEstudo em AnimaisInflamaçãoDoenças Cardiovasculares (DCV)Síndrome Metabólica+1
  61. 2021

    Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

  62. 2021

    Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation

  63. 2021

    Metabolic Consequences of Gestational Cannabinoid Exposure

  64. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  65. 2021

    Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity

    FavorávelEstudo em AnimaisDorInflamaçãoDor — CrônicaCanabigerol (CBG)
  66. 2021

    Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment

  67. 2021

    Targeting the endocannabinoid system with microbial interventions to improve gut integrity

  68. 2021

    The Current and Potential Application of Medicinal Cannabis Products in Dentistry

  69. 2021

    The Effects of Intermittent Hypoxic-Hyperoxic Exposures on Lipid Profile and Inflammation in Patients With Metabolic Syndrome

  70. 2021

    The gut microbiome, endocannabinoids and metabolic disorders

  71. 2021

    The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial

    FavorávelEnsaio Clínico Duplo-CegoEndocanabinoide (não especificado)
  72. 2021

    Understanding the possible role of endocannabinoid system in obesity

    FavorávelMetanáliseSíndrome MetabólicaEndocanabinoide (não especificado)
  73. 2021

    β-caryophyllene ameliorated obesity-associated airway hyperresponsiveness through some non-conventional targets

    FavorávelEstudo em Animais
  74. 2020

    An Unusual Case of Ventricular Tachycardia in a Young Patient Associated with Cannabis Use

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDependência — Cannabis+3
  75. 2020

    Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

  76. 2020

    Chronic Cannabidiol Administration Attenuates Skeletal Muscle De Novo Ceramide Synthesis Pathway and Related Metabolic Effects in a Rat Model of High-Fat Diet-Induced Obesity

    FavorávelEstudo em AnimaisDiabetesSíndrome Metabólica
  77. 2020

    Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat

  78. 2020

    Dietary Hemp Seeds More Effectively Attenuate Disorders in Genetically Obese Rats than Their Lipid Fraction

    FavorávelEstudo em AnimaisSíndrome Metabólica
  79. 2020

    Dual inhibition of cannabinoid CB 1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease

  80. 2020

    Effects of a high protein/low carbohydrate low-calorie diet versus a standard low-calorie diet on anthropometric parameters and cardiovascular risk factors, role of polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CB2R)

  81. 2020

    Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects

    FavorávelEnsaio Clínico Duplo-CegoDoenças Cardiovasculares (DCV)Estresse OxidativoInsônia e Distúrbios do Sono+2
  82. 2020

    Effects of Perioperative Cannabis Use on Bariatric Surgical Outcomes: a Systematic Review

    FavorávelMetanáliseEfeitos Adversos da Cannabis
  83. 2020

    Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?

  84. 2020

    Endocannabinoid system and cardiometabolic risk factors: A comprehensive systematic review insight into the mechanistic effects of omega-3 fatty acids

  85. 2020

    High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain

    FavorávelEstudo em AnimaisDiabetesCanabinoides Sintéticos SR-xTetraidrocanabivarina (THCV)
  86. 2020

    Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women

  87. 2020

    Lifetime Average Cannabis Use in Relation to Hypertriglyceridemic Waist Phenotype in U.S. Adults: A Population-Based Cross-Sectional Study

    FavorávelMetanálise
  88. 2020

    Meat Protein in High-Fat Diet Induces Adipogensis and Dyslipidemia by Altering Gut Microbiota and Endocannabinoid Dysregulation in the Adipose Tissue of Mice

    FavorávelEstudo em AnimaisDesequilíbrio do MicrobiomaMicrobioma
  89. 2020

    Mgll Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota

  90. 2020

    N-Acylphosphatidylethanolamines and N-acylethanolamines increase in saliva upon food mastication: the influence of the individual nutritional status and fat type in food

    FavorávelEnsaio ClínicoAnandamida (AEA)Endocanabinoide (não especificado)+2
  91. 2020

    Obesity Affects the Microbiota-Gut-Brain Axis and the Regulation Thereof by Endocannabinoids and Related Mediators

  92. 2020

    Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes

  93. 2020

    Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis

    FavorávelEstudo em AnimaisDepressãoSíndrome MetabólicaPalmitoiletanolamida (PEA)
  94. 2020

    Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets

  95. 2020

    Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

    FavorávelMetanáliseDiabetesSíndrome Metabólica
  96. 2020

    Prefrontal Cortex Neuromodulation Enhances Frontal Asymmetry and Reduces Caloric Intake in Patients with Morbid Obesity

    FavorávelEnsaio Clínico Duplo-CegoEndocanabinoide (não especificado)
  97. 2020

    Role of the endocannabinoid system in the regulation of the skeletal muscle response to exercise

  98. 2020

    Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

    FavorávelMetanálise
  99. 2020

    The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease

  100. 2020

    The effect of α-terpineol enantiomers on biomarkers of rats fed a high-fat diet

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoSíndrome Metabólica+1
  101. 2020

    Whey protein supplementation reducing fasting levels of anandamide and 2-AG without weight loss in pre-menopausal women with obesity on a weight-loss diet

  102. 2020

    Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

    FavorávelMetanáliseDiabetesEsteatose HepáticaTetraidrocanabivarina (THCV)
  103. 2019

    Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome

  104. 2019

    Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment

  105. 2019

    Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults

    FavorávelMetanáliseDiabetesSíndrome Metabólica
  106. 2019

    Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis

    FavorávelMetanáliseDorCâncerEsclerose Múltipla+7
  107. 2019

    Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding

  108. 2019

    Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications

  109. 2019

    The influence of the fatty acid amide hydrolase 385C>A single nucleotide polymorphisms on obesity susceptibility

  110. 2019

    Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention

  111. 2018

    A Phytol-Enriched Diet Activates PPAR-α in the Liver and Brown Adipose Tissue to Ameliorate Obesity-Induced Metabolic Abnormalities

    FavorávelEstudo em AnimaisSíndrome Metabólica
  112. 2018

    An Assessment of the Genotoxicity and Subchronic Toxicity of a Supercritical Fluid Extract of the Aerial Parts of Hemp

    FavorávelEstudo em AnimaisSíndrome Metabólica
  113. 2018

    Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review

  114. 2018

    Cannabis Therapeutics and the Future of Neurology

  115. 2018

    Common polymorphism in the cannabinoid receptor gene type 2 (CB2R) rs3123554 are associated with metabolic changes after two different hypocaloric diets with different dietary fatty profiles

    FavorávelEnsaio ClínicoSíndrome Metabólica
  116. 2018

    Effects of a Weight Loss Program on Metabolic Syndrome, Eating Disorders and Psychological Outcomes: Mediation by Endocannabinoids?

  117. 2018

    Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders

    InconclusivoMetanáliseEsquizofreniaSíndrome MetabólicaPerda de Apetite
  118. 2018

    Effects of polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CB2R) on metabolic and adiposity parameters after weight loss with two hypocaloric diets

  119. 2018

    Endocannabinoids in Body Weight Control

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+7
  120. 2018

    METABOLISM| APRIL 12 2018 Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue

  121. 2018

    Orosensory Detection of Dietary Fatty Acids Is Altered in CB1R−/− Mice

    FavorávelEstudo LaboratorialCaquexiaAnandamida (AEA)Canabinoides Sintéticos SR-x
  122. 2018

    Peripheral Endocannabinoids Associated With Energy Expenditure in Native Americans of Southwestern Heritage

  123. 2018

    Phytol Stimulates the Browning of White Adipocytes Through the Activation of AMP-activated Protein Kinase (AMPK) α in Mice Fed High-Fat Diet

    FavorávelEstudo em AnimaisSíndrome Metabólica
  124. 2018

    Polyunsaturated fatty acids and endocannabinoids in health and disease

  125. 2018

    Role of Cannabinoids in Obesity

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  126. 2018

    Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders

  127. 2018

    Spirulina maxima Extract Reduces Obesity through Suppression of Adipogenesis and Activation of Browning in 3T3-L1 Cells and High-Fat Diet-Induced Obese Mice

    FavorávelEstudo em AnimaisDiabetesSíndrome MetabólicaFicocianina
  128. 2018

    Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists

    InconclusivoEstudo LaboratorialSíndrome MetabólicaCanabinoide Sintético (não especificado)
  129. 2018

    Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users

  130. 2018

    Time-dependent effect of phytocannabinoid treatments in fat cells

    FavorávelEstudo LaboratorialDiabetesTetraidrocanabinol (THC)
  131. 2017

    Association between serum phospholipid fatty acid levels and adiposity in Mexican women

    FavorávelMetanáliseÁcido Pentadecanoico (C15:0)Pentadecanoilcarnitina (PDC)
  132. 2017

    Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity.

  133. 2017

    Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention

  134. 2017

    Incretin secretion in humans is under the influence of cannabinoid receptors

    InconclusivoEnsaio Clínico Duplo-CegoSíndrome MetabólicaTHC Farmacêutico
  135. 2017

    Low-fat yogurt consumption reduces biomarkers of chronic inflammation and inhibits markers of endotoxin exposure in healthy premenopausal women: a randomised controlled trial

  136. 2017

    Obesity-Related CKD: When Kidneys Get the Munchies

    InconclusivoMetanáliseDoença Renal Crônica
  137. 2017

    Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling

    FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
  138. 2016

    A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women

  139. 2016

    Cannabidiol promotes browning in 3T3-L1 adipocytes

    FavorávelEstudo LaboratorialSíndrome Metabólica
  140. 2016

    Cannabis - the Israeli perspective

  141. 2016

    Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome

  142. 2016

    Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation

  143. 2016

    Endocannabinoid System: A Multi-Facet Therapeutic Target.

  144. 2016

    Endocannabinoids in the gastrointestinal tract

  145. 2016

    Endocannabinoids--at the crossroads between the gut microbiota and host metabolism

  146. 2016

    Fetal Syndrome of Endocannabinoid Deficiency (FSECD) In Maternal Obesity

    InconclusivoMetanáliseGestação
  147. 2016

    Got Munchies? Estimating the Relationship between Marijuana Use and Body Mass Index.

    FavorávelMetanáliseDiabetesSíndrome MetabólicaPerda de Apetite
  148. 2016

    Interactions between dietary oil treatments and genetic variants modulate fatty acid ethanolamides in plasma and body weight composition

    FavorávelEnsaio Clínico Duplo-CegoSíndrome MetabólicaAnandamida (AEA)Endocanabinoide (não especificado)+3
  149. 2016

    Lysophosphatidylinositol Signalling and Metabolic Diseases

  150. 2016

    Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team

    FavorávelEnsaio ClínicoEndocanabinoide (não especificado)Dieta
  151. 2016

    Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

  152. 2016

    Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

  153. 2016

    Relation between postoperative ileus and anastomotic leakage after colorectal resection: a post hoc analysis of a prospective randomized controlled trial

  154. 2016

    Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-Arachidonoylglycerol

    InconclusivoEnsaio ClínicoInsônia e Distúrbios do SonoSíndrome Metabólica
  155. 2016

    The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers

    FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabivarina (THCV)
  156. 2016

    The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism

    FavorávelEstudo em AnimaisSíndrome MetabólicaCanabinoide Sintético (não especificado)
  157. 2016

    The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma

    InconclusivoEstudo LaboratorialCâncerCâncer — Linfoma2-Araquidonoilglicerol (2-AG)
  158. 2016

    β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties.

    FavorávelMetanáliseDorCâncerInflamação+16
  159. 2015

    Cannabis use in relation to obesity and insulin resistance in the Inuit population.

    FavorávelMetanáliseDiabetesSíndrome Metabólica
  160. 2015

    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers

    FavorávelEnsaio Clínico Duplo-CegoPerda de ApetiteTetraidrocanabivarina (THCV)
  161. 2015

    Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol.

    FavorávelEstudo em AnimaisDesequilíbrio do Microbioma
  162. 2015

    Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus

  163. 2014

    Capsaicin increases sensation of fullness in energy balance, and decreases desire to eat after dinner in negative energy balance

    FavorávelEnsaio ClínicoSíndrome MetabólicaCapsaicina (CAPS)
  164. 2014

    Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes

    FavorávelEnsaio ClínicoInflamaçãoEstresse OxidativoDiabetesCúrcuma+1
  165. 2014

    Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond

  166. 2014

    Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects

  167. 2014

    Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament

  168. 2014

    The endocannabinoid system and appetite: relevance for food reward

  169. 2013

    Acute effects of capsaicin on energy expenditure and fat oxidation in negative energy balance

    FavorávelEnsaio ClínicoEstresse OxidativoDietaCapsaicina (CAPS)
  170. 2013

    Addition of capsaicin and exchange of carbohydrate with protein counteract energy intake restriction effects on fullness and energy expenditure

  171. 2013

    Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men

    FavorávelEnsaio ClínicoÔmega-3
  172. 2013

    Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

  173. 2013

    Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia

  174. 2013

    Fat to treat fat: Emerging relationship between dietary PUFA, endocannabinoids, and obesity

    FavorávelMetanáliseSíndrome MetabólicaDieta
  175. 2013

    Preventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity

    FavorávelEstudo em AnimaisDiabetesSíndrome Metabólica
  176. 2013

    Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedadeDoenças Cardiovasculares (DCV)+7
  177. 2013

    The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

    FavorávelEstudo em AnimaisDiabetesCanabinoides Sintéticos AM-xTetraidrocanabivarina (THCV)
  178. 2013

    The Gastric CB1 Receptor Modulates Ghrelin Production through the mTOR Pathway to Regulate Food Intake.

    FavorávelEstudo em AnimaisAnorexia (perda de apetite)Canabinoides Sintéticos SR-x
  179. 2013

    The impact of marijuana use on glucose, insulin, and insulin resistance among US adults.

    FavorávelMetanáliseDiabetesSíndrome Metabólica
  180. 2012

    A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity

    DesfavorávelMetanálise ClínicaCanabinoides Sintéticos SR-x
  181. 2012

    Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis

  182. 2012

    CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans

  183. 2012

    Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue

  184. 2012

    Does rimonabant independently affect free fatty acid and glucose metabolism?

  185. 2012

    Efficacy of rimonabant in obese patients with binge eating disorder

  186. 2012

    Fatty acid flux and oxidation are increased by rimonabant in obese women

  187. 2012

    Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes

  188. 2012

    Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE)

  189. 2012

    The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity

  190. 2012

    The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity

    FavorávelMetanáliseSíndrome MetabólicaAnandamida (AEA)Exercício Físico
  191. 2011

    Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise

  192. 2011

    An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity

    InconclusivoMetanálise ClínicaCanabinoide Sintético (não especificado)
  193. 2011

    Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes

  194. 2011

    Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study

    DesfavorávelEnsaio Clínico Duplo-CegoEsquizofreniaTHC Farmacêutico
  195. 2011

    Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance

    FavorávelEnsaio Clínico Duplo-CegoDorAnsiedadeNáusea e VômitoCanabinoides Sintéticos CP-x+4
  196. 2011

    Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions

  197. 2011

    Obesity and cannabis use: results from 2 representative national surveys.

    FavorávelMetanálise
  198. 2011

    The fatty acid amide hydrolase (FAAH) gene variant rs324420 AA/AC is not associated with weight loss in a 1-year lifestyle intervention for obese children and adolescents

    InconclusivoEnsaio ClínicoHidrolase de Amidas de Ácidos Graxos (FAAH)
  199. 2010

    A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

    DesfavorávelEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  200. 2010

    A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

    InconclusivoEnsaio Clínico Duplo-Cego
  201. 2010

    A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

    DesfavorávelEnsaio Clínico Duplo-CegoDiabetes
  202. 2010

    A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet

    InconclusivoEnsaio Clínico Duplo-Cego
  203. 2010

    Depression-like phenotype following chronic CB1 receptor antagonism.

    DesfavorávelEstudo em AnimaisInflamaçãoDepressãoCanabinoides Sintéticos SR-xMedicina Mente-Corpo
  204. 2010

    Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist

    DesfavorávelMetanálise ClínicaCanabinoide Sintético (não especificado)
  205. 2010

    Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood

  206. 2010

    Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution

    DesfavorávelEnsaio ClínicoDiabetes
  207. 2010

    Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

    DesfavorávelEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  208. 2010

    The endocannabinoid system links gut microbiota to adipogenesis

  209. 2009

    Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands

    FavorávelEstudo LaboratorialCanabinoides Sintéticos CP-x
  210. 2009

    Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement

    DesfavorávelEnsaio ClínicoDiabetes
  211. 2009

    Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats

  212. 2009

    Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

  213. 2009

    Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology

    DesfavorávelMetanálise ClínicaEfeitos Adversos da CannabisHepatiteCanabinoides Sintéticos SR-x
  214. 2009

    The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists

    FavorávelEstudo em AnimaisCúrcuma
  215. 2008

    Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review

    DesfavorávelMetanálise ClínicaCanabinoides Sintéticos SR-x
  216. 2008

    Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

    FavorávelEnsaio Clínico Duplo-CegoCanabinoide Sintético (não especificado)
  217. 2008

    Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics

    FavorávelEnsaio Clínico Duplo-CegoGestaçãoCanabinoide Sintético (não especificado)
  218. 2008

    Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625

  219. 2008

    Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

    FavorávelEnsaio Clínico Duplo-Cego
  220. 2008

    Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers

    DesfavorávelEnsaio ClínicoCanabinoide Sintético (não especificado)
  221. 2008

    Obesity in adults

    DesfavorávelMetanálise ClínicaCanabinoides Sintéticos SR-x
  222. 2008

    Peripheral endocannabinoid system activity in patients treated with sibutramine

    DesfavorávelEnsaio Clínico Duplo-CegoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  223. 2008

    Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome

  224. 2008

    Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers

    InconclusivoEnsaio Clínico Duplo-Cego
  225. 2008

    The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity

    FavorávelMetanáliseAnsiedadeDepressãoEndocanabinoide (não especificado)
  226. 2007

    Cannabinoids in health and disease

  227. 2007

    High-cholesterol feeding aggravates cerebral infarction via decreasing the CB1 receptor

    FavorávelEstudo em AnimaisDiabetesSíndrome MetabólicaAVC+1
  228. 2007

    Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals

    DesfavorávelEnsaio Clínico Duplo-CegoHidrolase de Amidas de Ácidos Graxos (FAAH)
  229. 2007

    Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients

    FavorávelMetanálise ClínicaDiabetesCanabinoide Sintético (não especificado)
  230. 2007

    The endocannabinoid network: insight into the regulation of the neuroendocrine and metabolic systems

  231. 2006

    Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue

  232. 2006

    Rimonabant for overweight or obesity

    FavorávelMetanálise ClínicaCanabinoides Sintéticos SR-x
  233. 2005

    Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

    DesfavorávelEnsaio Clínico Duplo-CegoDoenças Cardiovasculares (DCV)Canabinoide Sintético (não especificado)
  234. 2004

    Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss

    FavorávelEstudo em AnimaisDiabetesSíndrome MetabólicaDelta-8-THC
  235. 2004

    Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-x
  236. 2002

    Tetrahydrocannabinol and endocannabinoids in feeding and appetite

  237. 2000

    Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats

    FavorávelEstudo em AnimaisSíndrome MetabólicaCanabinoides Sintéticos HU-x

Continue por aqui

Perguntas frequentes

Quantos estudos sobre obesidade estão indexados no acervo?
São 237 estudos, publicados entre 2000 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 85 · Estudo em Animais: 53 · Ensaio Clínico: 44 · Ensaio Clínico Duplo-Cego: 35 · Estudo Laboratorial: 11 · Metanálise Clínica: 9. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 174 favoráveis, 31 inconclusivos e 32 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Obesidade — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/obesidade/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Obesidade — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/obesidade/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.